Form 4: Cidara Therapeutics CEO Gifts Shares to Trust, DAF

Cidara Therapeutics President & CEO Jeffrey Stein reported multiple gift transfers of common stock to a trust and a donor-advised fund, alongside an Employee Stock Purchase Plan acquisition.

Summary

• Jeffrey Stein, President & CEO and Director of Cidara Therapeutics, Inc. (CDTX), reported several transactions involving the company's common stock.
• On December 10, 2025, 33,072 shares were transferred as a gift from direct ownership to a trust, resulting in 23,127 direct shares and 57,652 indirect shares held by the trust.
• On December 17, 2025, an additional 2,244 shares were transferred as a gift from direct ownership to the trust, leaving 20,883 direct shares and increasing the trust's indirect holdings to 59,896 shares.
• On December 18, 2025, 50 shares were acquired through the Issuer's Employee Stock Purchase Plan (ESPP).
• On December 19, 2025, 10,638 shares were transferred as a gift from direct ownership to the trust, resulting in 10,295 direct shares and 70,534 indirect shares held by the trust.
• On December 22, 2025, 5,425 shares were gifted from indirect ownership (by trust) to a donor-advised fund for charitable purposes, reducing the trust's indirect holdings to 65,109 shares.
• Following these transactions, Jeffrey Stein beneficially owns 10,295 shares directly, 65,109 shares indirectly through a trust, and 2,100 shares indirectly through his son, totaling 77,504 shares.

Sentiment

Score: 5

Explanation: The filing is a routine insider transaction report detailing gift transfers and an ESPP acquisition. It does not contain information that would significantly alter the company's financial outlook or operational sentiment.

Positives

• The acquisition of 50 shares through the Employee Stock Purchase Plan (ESPP) indicates participation in employee benefit programs.

Negatives

• The transactions primarily involve gift transfers, which reduce the reporting person's direct beneficial ownership in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects personal financial planning and charitable giving by a key executive.

Related Party Transactions

• Gift transfers of common stock from Jeffrey Stein to a trust, which is typically considered a related party transaction for beneficial ownership reporting purposes.

Stakeholder Impact

• Shareholders: The transactions represent a restructuring of beneficial ownership by a key executive, with no direct impact on the company's outstanding shares or market capitalization. The reduction in direct ownership is offset by increased indirect ownership through a trust, indicating continued beneficial interest.
• Employees: The acquisition of shares via the Employee Stock Purchase Plan (ESPP) highlights management's participation in employee benefit programs.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Form 4, Insider Transaction, Jeffrey Stein, CEO, Director, Stock Gift, Beneficial Ownership, Trust, Donor-Advised Fund, ESPP